Director — John C. Reed, M.D., Ph.D.: The filing discloses the routine election of a new independent director to fill a vacancy created by an expansion of the board size.

Results of Operations and Financial Condition. On July 30, 2026, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18…

The filing details the approval of stock plans and a deferred compensation plan, which are routine corporate actions.

Results of Operations and Financial Condition. On May 6, 2026, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 o…

Director — Julian C. Baker, Daniel J. Brennan: Reclassification of directors to achieve a more equal apportionment among the three classes.

Results of Operations and Financial Condition. On February 19, 2026, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for…

Entry into a Material Definitive Agreement. On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche. Pursuant to the terms of the Amendment, effective as of the Effective Date, the Company will have the full and excl…

Senior Vice President and Chief Accounting Officer — Rita Thakkar: The company appointed Rita Thakkar as Senior Vice President and Chief Accounting Officer, a significant leadership addition.

Results of Operations and Financial Condition. On November 4, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes…

Results of Operations and Financial Condition. On August 5, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Sec…

Entry into a Material Definitive Agreement. On July 17, 2025 (the “ Closing Date ”), Madrigal Pharmaceuticals, Inc. (the “ Company ”) as the borrower and its wholly owned subsidiary, Canticle Pharmaceuticals, Inc., as a guarantor (the “ Guarantor ”), entered into a Financing Agreement (the “ Financing Agreement ”) with certain funds managed by Blue Owl Capital Corporation, as the lenders (the “ Lenders ”), and LSI Financing LLC, as the administrative agent for the Lenders (the “ Administrativ…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Termination of Material Definitive Agreement. On July 17, 2025, the Company used the proceeds of the Initial Term Loan funded by the Lenders upon the closing under the Financing Agreement to repay all outstanding obligations, totaling $121.6 million, under that certain Loan and Security 2 Agreement, dated as of May 9, 2022, by and among the Company, the Guarantor, the several banks and other financial institutions or entities from time to time thereto and Hercules Capital, Inc., as amended (t…

Results of Operations and Financial Condition. On May 1, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Secti…

Chief Medical Officer and President of Research and Development — Dr. Rebecca Taub: Dr. Rebecca Taub is transitioning from her current role to a Senior Scientific and Medical Advisor position.

Director — Fred Craves, Ph.D.: Dr. Fred Craves resigned from the Board of Directors and was succeeded by Dr. Jackie Fouse.

Results of Operations and Financial Condition. On February 26, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter and year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for…

Results of Operations and Financial Condition. On January 13, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) announced preliminary fourth quarter and full-year 2024 net sales and year-end cash and provided additional corporate updates. The Company reported preliminary fourth-quarter and full-year 2024 Rezdiffra ™ (resmetirom) net sales in the range of $100 million to $103 million and $177 million to $180 million, respectively. The Company also reported preliminary cash, cash equivalents…

Results of Operations and Financial Condition. On October 31, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of…

Results of Operations and Financial Condition. On August 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Sectio…

The filing describes an amendment to the stock plan, not a management change.

Termination of a Material Definitive Agreement. The information set forth in

Other Events On May 7, 2024, the Company filed a prospectus supplement to the prospectus that forms a part of the Registration Statement registering the sale from time to time by the selling stockholder named therein of up to 7,045,385 shares of Common Stock. The Company will not receive any proceeds from the sale of the Common Stock by the selling stockholder. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock nor sha…

Entry into a Material Definitive Agreement. On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC, (“TD Cowen”), pursuant to which the Company may issue and sell through or to TD Cowen, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time having an aggregate sales price of up to $300,000,000 (the “ATM Offering”). Sales…

Results of Operations and Financial Condition. On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Secti…